# OnCo record nct06888674 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06888674/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06888674", "NCT06888674" ;
  schema:name "Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer."@en ;
  schema:description "A phase 1/2 trial of gemcitabine, capecitabine and sintilimab in pancreatic cancer, run by Zhejiang University, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06888674/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06888674> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "pancreatic-deep-dive" ;
  onco:phase "1/2" ;
  onco:cancers <https://onco.cc/cancers/resectable-pdac/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/sintilimab/> .